| 0.75 0.029 (3.96%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.05 | 1-year : | 1.37 |
| Resists | First : | 0.9 | Second : | 1.17 |
| Pivot price | 0.83  |
|||
| Supports | First : | 0.46 | Second : | 0.38 |
| MAs | MA(5) : | 0.7  |
MA(20) : | 0.81 |
| MA(100) : | 1.23 |
MA(250) : | 1.88 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.2 |
D(3) : | 15.6 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 4.44 | Low : | 0.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PROK ] has closed above bottom band by 33.9%. Bollinger Bands are 22% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.79 - 0.8 | 0.8 - 0.8 |
| Low: | 0.7 - 0.71 | 0.71 - 0.71 |
| Close: | 0.74 - 0.75 | 0.75 - 0.76 |
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Mon, 12 May 2025
PROKIDNEY CORP. SEC 10-Q Report - TradingView
Mon, 12 May 2025
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights - Stock Titan
Tue, 08 Apr 2025
PROK stock touches 52-week low at $0.49 amid market challenges - Investing.com
Mon, 07 Apr 2025
Institutional owners may take dramatic actions as ProKidney Corp.'s (NASDAQ:PROK) recent 32% drop adds to one-year losses - simplywall.st
Thu, 27 Mar 2025
Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation - Yahoo Finance
Tue, 18 Mar 2025
ProKidney Corp (PROK) Reports $163.3 Million Net Loss for 2024, - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 130 (M) |
| Held by Insiders | 7.816e+007 (%) |
| Held by Institutions | 30 (%) |
| Shares Short | 11,930 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7292e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -67 % |
| Return on Assets (ttm) | 856.5 % |
| Return on Equity (ttm) | -25.9 % |
| Qtrly Rev. Growth | 76000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -26.08 |
| EBITDA (p.s.) | 48101.3 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -126 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | -0.16 |
| Dividend | 0 |
| Forward Dividend | 1.564e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|